Overactive Bladder Clinical Trial
Official title:
Hypnotherapy for Treatment of Overactive Bladder: A Feasibility Study
The investigators purpose is to perform a pilot study evaluating the efficacy in hypnotherapy in treating women with Overactive Bladder Symptoms (urinary urgency symptoms and urinary frequency). Approximately half the women in the study will receive "standard care" (performing a voiding diary, Pelvic Floor exercises, and timed voiding) and the other half will receive "standard care" and 3 hypnotherapy sessions. The investigators will compare the groups using a validated overactive bladder questionnaire and compare voiding diaries to evaluate urinary frequency at the end of the sessions/study completion.
Experimental Design and Methods:
i) This is a feasibility study (prior to performing a larger randomized controlled trial at a
later date) evaluating whether hypnotherapy effectively treats Overactive Bladder (OAB).
Ultimately, for the larger study, in order to find a 20% difference between the hypnotherapy
group and controls, we will need to evaluate a total of approximately 66-70 women to find a
20% difference between groups, assuming 80% power and P=0.05. However, the purpose of this
pilot study is to evaluate the feasibility of the larger study and determine the appropriate
control intervention and outcomes. We plan to evaluate approximately ten subjects
(approximately twenty overall) in both the control and hypnotherapy groups.
ii) Patients OAB will be offered entry into the study. a) Inclusion criteria: women
experiencing 8 voids/day and an OAB Awareness tool score greater than 8. b) Exclusion
criteria: males (since we do not care for males in the gynecology clinic), non-English
speakers, pregnant women, women younger than 18 years old, incarcerated women, women with a
history of bipolar disorder or schizophrenia, women unwilling to undergo hypnotherapy iii)
Informed consent will be obtained. iv) Prior to receiving interventions, patients will be
administered the OAB-q & instructed to keep a 3 day voiding diary. If the patient has not had
a pelvic exam in the urogynecology clinic within the last year, a pelvic exam will be
performed.
v) The usual standard treatments for OAB include pelvic floor exercise, voiding diaries,
bladder drills (increasing time between voids), and anti-cholinergic medications. The control
group will be offered any or all of our standard treatments, including Behavioral treatment
(review of voiding diaries and instruction regarding behavioral changes). Both groups will be
allowed to continue current OAB medications but asked not to start new medications. The
hypnotherapy group will also be offered any or all of our standard treatments, but they will
be given the option of receiving hypnotherapy in addition to the usual treatments.
vi) Hypnotherapy sessions: Dr. Sapien will conduct 3 hypnotherapy session to women randomized
to the hypnotherapy group. These sessions will occur approximately every1-2 weeks over
approximately a time span of 6-8 weeks. The sessions will last 60-90 minutes. Session #1)
Explain hypnotherapy and practice suggestion therapy; Session #2) address emotions around OAB
and life impact, visualization of pelvic floor exercise mechanics, teach self hypnosis;
Session #3) address emotions, further practice on exercises and self-hypnosis vii) Blinding
of Investigators and Allocation Concealment: Randomization will be performed by the CTSC
using computer generated allocation. Only the CTSC personnel will know the assignment schema.
Researchers will not know the group assignments. A research nurse otherwise uninvolved in the
study will place the group assignments in serially numbered, opaque envelopes. Once subjects
sign consents they will receive an opaque envelop assigning them to the Behavioral Therapy or
Hypnotherapy group. The individual responsible for data collection and data entry will not
know the group assignment until the end of the study when the assignment code is broken.
VI. Human Subjects:
i) See inclusion & exclusion criteria described previously. Children, prisoners and mentally
ill or disabled subjects will be excluded from our study. Women who are pre-menopausal and
who are not using contraception and have missed a menstrual period will be offered a
pregnancy test in the clinic, as is the standard of care in the gynecology clinic. Pregnancy
is an exclusion criteria for study participation.Women evaluated in the Gynecology Clinic at
the University of New Mexico will be offered participation in the study.
ii) Women will be offered study participation in a private setting at their gynecology visit
if have the symptoms of OAB noted previously (V.ii).The study will be described verbally and
they will receive a copy of the consent form to read. They will be given the option of taking
the consent home to have time to consider whether they would like to participate. If the
patient wishes more time to consider whether she would like to participate, she will be asked
whether she would agree to phone follow-up by a study investigator. If she agrees, she will
have phone follow-up at least 24 hours after her clinic visit. If the patient expresses
interest in participating in the study, she will then return to sign her consent with a study
investigator. All patients will be reassured that declining study participation will have no
effect on the care that they receive iii) Potential Risks of Hypnotherapy: Potential Risks of
Hypnotherapy: Risks of hypnotherapy are minimal. Hypnosis is a natural state of mind in which
the subconscious is accessed and utilized to make a positive impact. Although, in the 1980
false memory syndrome was described with the use of hypnotherapy in child abuse survivors,
the current practice of hypnotherapy uses a much different approach to this therapeutic
application. Current practice includes open-ended lines of questioning as opposed to
suggestive or leading lines of questioning utilized with these victims.
Risks will be minimized by using open-ended lines of questioning for all hypnotherapy
sessions (see above). For this study the hypnotherapist is also a physician, therefore
physician-patient confidentiality guidelines are in place. Subjects will be asked to contact
the PI if they believe that they are suffering from a psychological burden which has occurred
from their involvement in the study.
It is highly unlikely that this study would be terminated, as the risks to participants are
minimal. However, in the unlikely circumstance that a large number of hypnotherapy subjects
complain of severe psychologic or physical discomfort with their hypnotherapy sessions
(despite incorporation of relaxation techniques in the sessions), the study would be
terminated. Subject case discussion will be conducted by the research team in a private
setting
Potential Risks to Control Group: The control group will be offered standard care for
treatment of OAB and will not be exposed to any greater risk than usual for OAB treatments
iv) Potential Benefits of Hypnotherapy: Alleviating or diminishing symptoms of frequent
urinary, urinary urgency and urine leakage.
v)Safety Oversite: The investigators will meet approximately monthly to review study progress
and subject issues/complaints. The subjects will have follow-up with either phone or
in-person contact with the hypnotherapist or CTSC personnel. If major events, though
unlikely, occur, they will be reviewed with appropriate CTSC and HRRC personnel.
vi) After the study is finished, the patients in the control group have the option of
undergoing an approx. 20 minute relaxation hypnotherapy session with Dr. Sapien.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Completed |
NCT01122563 -
A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
|
N/A |